Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Ishita Drugs and Industries has informed that the Board of Directors of the company, at its meeting held today 14th November, 2022 have: Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022. The company has enclosed Limited Review Report of the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022 issued by the Statutory Auditors of the Company.
The above information is a part of company’s filings submitted to BSE.
